{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:46:40Z","timestamp":1793375200362,"version":"4.5.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00280-019-03884-5","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T05:03:06Z","timestamp":1560834186000},"page":"471-485","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":120,"title":["Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review"],"prefix":"10.1007","volume":"84","author":[{"given":"Marie Lindhard","family":"Madsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Due","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Ejskj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paw","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Dybk\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,18]]},"reference":[{"key":"3884_CR1","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.12659\/MSM.893142","volume":"21","author":"L Yang","year":"2015","unstructured":"Yang L, Yu L, Chen X, Hu Y, Wang B (2015) Clinical analysis of adverse drug reactions between vincristine and triazoles in children with acute lymphoblastic leukemia. Med Sci Monit 21:1656\u20131661. \n                    https:\/\/doi.org\/10.12659\/MSM.893142","journal-title":"Med Sci Monit"},{"issue":"3","key":"3884_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1040-8428(98)00023-7","volume":"29","author":"CE Gidding","year":"1999","unstructured":"Gidding CE, Kellie SJ, Kamps WA, de Graaf SS (1999) Vincristine revisited. Crit Rev Oncol Hematol 29(3):267\u2013287","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"3884_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0163-7258(91)90004-6","volume":"52","author":"JJ Correia","year":"1991","unstructured":"Correia JJ (1991) Effects of antimitotic agents on tubulin\u2013nucleotide interactions. Pharmacol Ther 52(2):127\u2013147","journal-title":"Pharmacol Ther"},{"issue":"2","key":"3884_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ccr.2008.07.002","volume":"14","author":"KE Gascoigne","year":"2008","unstructured":"Gascoigne KE, Taylor SS (2008) Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14(2):111\u2013122. \n                    https:\/\/doi.org\/10.1016\/j.ccr.2008.07.002","journal-title":"Cancer Cell"},{"key":"3884_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-017-0003-3","author":"A Gutierrez-Camino","year":"2017","unstructured":"Gutierrez-Camino A, Umerez M, Martin-Guerrero I, Garcia de Andoin N, Santos B, Sastre A, Echebarria-Barona A, Astigarraga I, Navajas A, Garcia-Orad A (2017) Mir-pharmacogenetics of vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia. Pharmacogenom J. \n                    https:\/\/doi.org\/10.1038\/s41397-017-0003-3","journal-title":"Pharmacogenom J"},{"issue":"1","key":"3884_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00277-015-2514-9","volume":"95","author":"Y Utsu","year":"2016","unstructured":"Utsu Y, Takaishi K, Inagaki S, Arai H, Yuasa H, Masuda S, Matsuura Y, Aotsuka N, Wakita H (2016) Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma. Ann Hematol 95(1):41\u201347. \n                    https:\/\/doi.org\/10.1007\/s00277-015-2514-9","journal-title":"Ann Hematol"},{"issue":"11","key":"3884_CR7","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00277-018-3437-z","volume":"97","author":"C Morth","year":"2018","unstructured":"Morth C, Valachis A, Sabaa AA, Molin D, Flogegard M, Enblad G (2018) Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome? Ann Hematol 97(11):2129\u20132135. \n                    https:\/\/doi.org\/10.1007\/s00277-018-3437-z","journal-title":"Ann Hematol"},{"issue":"3","key":"3884_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/neu.480110304","volume":"11","author":"SY Chan","year":"1980","unstructured":"Chan SY, Worth R, Ochs S (1980) Block of axoplasmic transport in vitro by vinca alkaloids. J Neurobiol 11(3):251\u2013264. \n                    https:\/\/doi.org\/10.1002\/neu.480110304","journal-title":"J Neurobiol"},{"issue":"4","key":"3884_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MPH.0000000000000825","volume":"39","author":"M Kavcic","year":"2017","unstructured":"Kavcic M, Koritnik B, Krzan M, Velikonja O, Prelog T, Stefanovic M, Debeljak M, Jazbec J (2017) Electrophysiological studies to detect peripheral neuropathy in children treated with vincristine. J Pediatr Hematol Oncol 39(4):266\u2013271. \n                    https:\/\/doi.org\/10.1097\/MPH.0000000000000825","journal-title":"J Pediatr Hematol Oncol"},{"issue":"8","key":"3884_CR10","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/MPH.0b013e3181e9038d","volume":"32","author":"GM Mokhtar","year":"2010","unstructured":"Mokhtar GM, Shaaban SY, Elbarbary NS, Fayed WA (2010) A trial to assess the efficacy of glutamic acid in prevention of vincristine-induced neurotoxicity in pediatric malignancies: a pilot study. J Pediatr Hematol Oncol 32(8):594\u2013600. \n                    https:\/\/doi.org\/10.1097\/MPH.0b013e3181e9038d","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"3884_CR11","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/01.mph.0000165130.21539.a3","volume":"27","author":"M El Hayek","year":"2005","unstructured":"El Hayek M, Trad O, Jamil A (2005) Vincristine-induced urinary bladder paralysis. J Pediatr Hematol Oncol 27(5):286\u2013287. \n                    https:\/\/doi.org\/10.1097\/01.mph.0000165130.21539.a3","journal-title":"J Pediatr Hematol Oncol"},{"issue":"11","key":"3884_CR12","first-page":"6731","volume":"34","author":"S Adhikari","year":"2014","unstructured":"Adhikari S, Dongol RM, Hewett Y, Shah BK (2014) Vincristine-induced blindness: a case report and review of literature. Anticancer Res 34(11):6731\u20136733","journal-title":"Anticancer Res"},{"issue":"2","key":"3884_CR13","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/0002-9394(76)90725-X","volume":"81","author":"PA Sanderson","year":"1976","unstructured":"Sanderson PA, Kuwabara T, Cogan DG (1976) Optic neuropathy presumably caused by vincristine therapy. Am J Ophthalmol 81(2):146\u2013150","journal-title":"Am J Ophthalmol"},{"key":"3884_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3928\/01913913-20150629-01","volume":"52","author":"AH Palkar","year":"2015","unstructured":"Palkar AH, Nair AG, Desai RJ, Potdar NA, Shinde CA (2015) Vincristine-induced neuropathy presenting as ptosis and ophthalmoplegia in a 2-year-old boy. J Pediatr Ophthalmol Strabismus 52:34\u201337. \n                    https:\/\/doi.org\/10.3928\/01913913-20150629-01","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"6","key":"3884_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/bf02759902","volume":"73","author":"A Bay","year":"2006","unstructured":"Bay A, Yilmaz C, Yilmaz N, Oner AF (2006) Vincristine induced cranial polyneuropathy. Indian J Pediatr 73(6):531\u2013533. \n                    https:\/\/doi.org\/10.1007\/bf02759902","journal-title":"Indian J Pediatr"},{"issue":"4","key":"3884_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000204462","volume":"90","author":"T Soysal","year":"1993","unstructured":"Soysal T, Ferhanoglu B, Bilir M, Akman N (1993) Oculomotor nerve palsy associated with vincristine treatment. Acta Haematol 90(4):209\u2013210","journal-title":"Acta Haematol"},{"issue":"1","key":"3884_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaapos.2003.07.010","volume":"8","author":"SC Lash","year":"2004","unstructured":"Lash SC, Williams CPR, Marsh CS, Crithchley C, Hodgkins PR, MacKie EJ (2004) Acute sixth-nerve palsy after vincristine therapy. J AAPOS 8(1):67\u201368. \n                    https:\/\/doi.org\/10.1016\/j.jaapos.2003.07.010","journal-title":"J AAPOS"},{"issue":"1","key":"3884_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/s1091853103003239","volume":"8","author":"E Toker","year":"2004","unstructured":"Toker E, Yenice O, Ogut MS (2004) Isolated abducens nerve palsy induced by vincristine therapy. J AAPOS 8(1):69\u201371. \n                    https:\/\/doi.org\/10.1016\/s1091853103003239","journal-title":"J AAPOS"},{"issue":"8","key":"3884_CR19","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/j.leukres.2010.01.026","volume":"34","author":"N Ngamphaiboon","year":"2010","unstructured":"Ngamphaiboon N, Sweeney R, Wetzler M, Wang ES (2010) Pyridoxine treatment of vincristine-induced cranial polyneuropathy in an adult patient with acute lymphocytic leukemia: case report and review of the literature. Leuk Res 34(8):e194\u2013e196. \n                    https:\/\/doi.org\/10.1016\/j.leukres.2010.01.026","journal-title":"Leuk Res"},{"issue":"10","key":"3884_CR20","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1002\/1097-0142(19810515)47:10<2404::AID-CNCR2820471014>3.0.CO;2-2","volume":"47","author":"SL Mahajan","year":"1981","unstructured":"Mahajan SL, Ikeda Y, Myers TJ, Baldini MG (1981) Acute acoustic nerve palsy associated with vincristine therapy. Cancer 47(10):2404\u20132406","journal-title":"Cancer"},{"issue":"1","key":"3884_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ijporl.2006.09.001","volume":"71","author":"M Riga","year":"2007","unstructured":"Riga M, Psarommatis I, Korres S, Varvutsi M, Giotakis I, Apostolopoulos N, Ferekidis E (2007) Neurotoxicity of vincristine on the medial olivocochlear bundle. Int J Pediatr Otorhinolaryngol 71(1):63\u201369. \n                    https:\/\/doi.org\/10.1016\/j.ijporl.2006.09.001","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"5","key":"3884_CR22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/MPH.0b013e3181e01584","volume":"32","author":"ZA Latiff","year":"2010","unstructured":"Latiff ZA, Kamal NA, Jahendran J, Alias H, Goh BS, Syed Zakaria SZ, Jamal R (2010) Vincristine-induced vocal cord palsy: case report and review of the literature. J Pediatr Hematol Oncol 32(5):407\u2013410. \n                    https:\/\/doi.org\/10.1097\/MPH.0b013e3181e01584","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6071","key":"3884_CR23","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1136\/bmj.1.6071.1251","volume":"1","author":"JA Whittaker","year":"1977","unstructured":"Whittaker JA, Griffith IP (1977) Recurrent laryngeal nerve paralysis in patients receiving vincristine and vinblastine. BMJ 1(6071):1251\u20131252","journal-title":"BMJ"},{"issue":"3","key":"3884_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/BF00179439","volume":"3","author":"W Scheithauer","year":"1985","unstructured":"Scheithauer W, Ludwig H, Maida E (1985) Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report. Invest New Drugs 3(3):315\u2013318","journal-title":"Invest New Drugs"},{"issue":"6","key":"3884_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/nrl.0000000000000105","volume":"21","author":"J How","year":"2016","unstructured":"How J, Blattner M, Fowler S, Wang-Gillam A, Schindler SE (2016) Chemotherapy-associated posterior reversible encephalopathy syndrome: a case report and review of the literature. Neurologist 21(6):112\u2013117. \n                    https:\/\/doi.org\/10.1097\/nrl.0000000000000105","journal-title":"Neurologist"},{"issue":"4","key":"3884_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/BF00313556","volume":"229","author":"K Tomiwa","year":"1983","unstructured":"Tomiwa K, Mikawa H, Hazama F, Yazawa K, Hosoya R, Ohya T, Nishimura K (1983) Syndrome of inappropriate secretion of antidiuretic hormone caused by vincristine therapy: a case report of the neuropathology. J Neurol 229(4):267\u2013272","journal-title":"J Neurol"},{"issue":"5","key":"3884_CR27","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/archinte.1973.03650110061013","volume":"132","author":"GL Robertson","year":"1973","unstructured":"Robertson GL, Bhoopalam N, Zelkowitz LJ (1973) Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone. Arch Intern Med 132(5):717\u2013720","journal-title":"Arch Intern Med"},{"issue":"6","key":"3884_CR28","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/cncr.10397","volume":"94","author":"SJ Kellie","year":"2002","unstructured":"Kellie SJ, Barbaric D, Koopmans P, Earl J, Carr DJ, de Graaf SS (2002) Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration. Cancer 94(6):1815\u20131820","journal-title":"Cancer"},{"issue":"3","key":"3884_CR29","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","volume":"109","author":"A Moghrabi","year":"2007","unstructured":"Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, Samson Y, Schorin M, Dalton VK, Lipshultz SE, Neuberg DS, Gelber RD, Cohen HJ, Sallan SE, Silverman LB (2007) Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109(3):896\u2013904. \n                    https:\/\/doi.org\/10.1182\/blood-2006-06-027714","journal-title":"Blood"},{"issue":"12","key":"3884_CR30","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00520-010-1043-2","volume":"19","author":"AL Kautio","year":"2011","unstructured":"Kautio AL, Haanp\u00e4\u00e4 M, Kautiainen H, Kalso E, Saarto T (2011) Burden of chemotherapy-induced neuropathy-a cross-sectional study. Support Care Cancer 19(12):1991\u20131996. \n                    https:\/\/doi.org\/10.1007\/s00520-010-1043-2","journal-title":"Support Care Cancer"},{"issue":"4","key":"3884_CR31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. Ann Intern Med 151(4):264\u2013269. \n                    https:\/\/doi.org\/10.7326\/0003-4819-151-4-200908180-00135","journal-title":"Ann Intern Med"},{"issue":"3","key":"3884_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ejpn.2017.12.019","volume":"22","author":"S Lieber","year":"2018","unstructured":"Lieber S, Blankenburg M, Apel K, Hirschfeld G, Hernaiz Driever P, Reindl T (2018) Small-fiber neuropathy and pain sensitization in survivors of pediatric acute lymphoblastic leukemia. Eur J Paediatr Neurol EJPN 22(3):457\u2013469. \n                    https:\/\/doi.org\/10.1016\/j.ejpn.2017.12.019","journal-title":"Eur J Paediatr Neurol EJPN"},{"issue":"3","key":"3884_CR33","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00520-012-1591-8","volume":"21","author":"LS Gilchrist","year":"2013","unstructured":"Gilchrist LS, Tanner L (2013) The pediatric-modified total neuropathy score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers. Support Care Cancer 21(3):847\u2013856. \n                    https:\/\/doi.org\/10.1007\/s00520-012-1591-8","journal-title":"Support Care Cancer"},{"issue":"2","key":"3884_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00520-013-1981-6","volume":"22","author":"LS Gilchrist","year":"2014","unstructured":"Gilchrist LS, Marais L, Tanner L (2014) Comparison of two chemotherapy-induced peripheral neuropathy measurement approaches in children. Support Care Cancer 22(2):359\u2013366. \n                    https:\/\/doi.org\/10.1007\/s00520-013-1981-6","journal-title":"Support Care Cancer"},{"issue":"5","key":"3884_CR35","doi-asserted-by":"publisher","first-page":"E49","DOI":"10.1097\/NCC.0b013e318299ad23","volume":"36","author":"EM Lavoie Smith","year":"2013","unstructured":"Lavoie Smith EM, Li L, Hutchinson RJ, Ho R, Burnette WB, Wells E, Bridges C, Renbarger J (2013) Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs 36(5):E49\u2013E60. \n                    https:\/\/doi.org\/10.1097\/NCC.0b013e318299ad23","journal-title":"Cancer Nurs"},{"issue":"4","key":"3884_CR36","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/1097-0142(19890815)64:4<801::AID-CNCR2820640406>3.0.CO;2-E","volume":"64","author":"HE Hirvonen","year":"1989","unstructured":"Hirvonen HE, Salmi TT, Heinonen E, Antila KJ, Valimaki IA (1989) Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy. Cancer 64(4):801\u2013805","journal-title":"Cancer"},{"issue":"2\u20133","key":"3884_CR37","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/0022-510X(80)90179-3","volume":"45","author":"P Guiheneuc","year":"1980","unstructured":"Guiheneuc P, Ginet J, Groleau JY, Rojouan J (1980) Early phase of vincristine neuropathy in man. Electrophysiological evidence for a dying-back phenomenon, with transitory enhancement of spinal transmission of the monosynaptic reflex. J Neurol Sci 45(2\u20133):355\u2013366","journal-title":"J Neurol Sci"},{"issue":"4","key":"3884_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3233\/JPN-2009-0333","volume":"7","author":"V Toopchizadeh","year":"2009","unstructured":"Toopchizadeh V, Barzegar M, Rezamand A, Feiz AH (2009) Electrophysiological consequences of vincristine contained chemotherapy in children: a cohort study. J Pediatr Neurol 7(4):351\u2013356. \n                    https:\/\/doi.org\/10.3233\/JPN-2009-0333","journal-title":"J Pediatr Neurol"},{"issue":"6","key":"3884_CR39","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/mus.24647","volume":"52","author":"H Courtemanche","year":"2015","unstructured":"Courtemanche H, Magot A, Ollivier Y, Rialland F, Leclair-Visonneau L, Fayet G, Camdessanche JP, Pereon Y (2015) Vincristine-induced neuropathy: atypical electrophysiological patterns in children. Muscle Nerve 52(6):981\u2013985. \n                    https:\/\/doi.org\/10.1002\/mus.24647","journal-title":"Muscle Nerve"},{"issue":"3","key":"3884_CR40","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1529-8027.2009.00230.x","volume":"14","author":"S Ramchandren","year":"2009","unstructured":"Ramchandren S, Leonard M, Mody RJ, Donohue JE, Moyer J, Hutchinson R, Gurney JG (2009) Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Periph Nerv Syst JPNS 14(3):184\u2013189. \n                    https:\/\/doi.org\/10.1111\/j.1529-8027.2009.00230.x","journal-title":"J Periph Nerv Syst JPNS"},{"key":"3884_CR41","doi-asserted-by":"crossref","unstructured":"Kava M, Walsh P, SrinivasJois R, Cole C, Lewis B, Nagarajan L (2017) Clinical and electrophysiological characteristics of vincristine induced peripheral neuropathy in children during cancer chemotherapy: does vitamin E have a role. JICNA 17 (75)","DOI":"10.17724\/jicna.2017.75"},{"issue":"8","key":"3884_CR42","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","volume":"41","author":"TJ Postma","year":"2005","unstructured":"Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lanteri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer (Oxford, England: 1990) 41(8):1135\u20131139. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2005.02.012","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"11","key":"3884_CR43","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1007\/s00520-017-3780-y","volume":"25","author":"J Le-Rademacher","year":"2017","unstructured":"Le-Rademacher J, Kanwar R, Seisler D, Pachman DR, Qin R, Abyzov A, Ruddy KJ, Banck MS, Lavoie Smith EM, Dorsey SG, Aaronson NK, Sloan J, Loprinzi CL, Beutler AS (2017) Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel\/carboplatin-induced peripheral neuropathy in NCCTG\/Alliance clinical trials. Supportive Care Cancer 25(11):3537\u20133544. \n                    https:\/\/doi.org\/10.1007\/s00520-017-3780-y","journal-title":"Supportive Care Cancer"},{"issue":"7","key":"3884_CR44","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/pbc.23039","volume":"57","author":"DL Anghelescu","year":"2011","unstructured":"Anghelescu DL, Faughnan LG, Jeha S, Relling MV, Hinds PS, Sandlund JT, Cheng C, Pei D, Hankins G, Pauley JL, Pui CH (2011) Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 57(7):1147\u20131153. \n                    https:\/\/doi.org\/10.1002\/pbc.23039","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"3884_CR45","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/0883073814535495","volume":"30","author":"P Jain","year":"2015","unstructured":"Jain P, Gulati S, Toteja GS, Bakhshi S, Seth R, Pandey RM (2015) Serum alpha tocopherol, vitamin B12, and folate levels in childhood acute lymphoblastic leukemia survivors with and without neuropathy. J Child Neurol 30(6):786\u2013788. \n                    https:\/\/doi.org\/10.1177\/0883073814535495","journal-title":"J Child Neurol"},{"issue":"2","key":"3884_CR46","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/BF00255486","volume":"8","author":"ZR Desai","year":"1982","unstructured":"Desai ZR, Van den Berg HW, Bridges JM, Shanks RG (1982) Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 8(2):211\u2013214","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"3884_CR47","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/COC.0b013e3181e1d0c0","volume":"34","author":"A Brunello","year":"2011","unstructured":"Brunello A, Kapoor R, Extermann M (2011) Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. Am J Clin Oncol 34(3):292\u2013296. \n                    https:\/\/doi.org\/10.1097\/COC.0b013e3181e1d0c0","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"3884_CR48","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/cncr.20071","volume":"100","author":"MA Weiser","year":"2004","unstructured":"Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O\u2019Brien SM (2004) Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone\/methotrexate-cytarabine regimen. Cancer 100(6):1179\u20131185. \n                    https:\/\/doi.org\/10.1002\/cncr.20071","journal-title":"Cancer"},{"issue":"9","key":"3884_CR49","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/CAD.0b013e32833db89d","volume":"21","author":"Y Kanbayashi","year":"2010","unstructured":"Kanbayashi Y, Hosokawa T, Okamoto K, Konishi H, Otsuji E, Yoshikawa T, Takagi T, Taniwaki M (2010) Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis. Anticancer Drugs 21(9):877\u2013881. \n                    https:\/\/doi.org\/10.1097\/CAD.0b013e32833db89d","journal-title":"Anticancer Drugs"},{"issue":"3","key":"3884_CR50","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/0284186X.2017.1415462","volume":"57","author":"MJ Iba\u00f1ez-Juli\u00e1","year":"2018","unstructured":"Iba\u00f1ez-Juli\u00e1 MJ, Berzero G, Reyes-Botero G, Maisonobe T, Lenglet T, Slim M, Louis S, Balaguer A, Sanson M, Le Guern E, Latour P, Ricard D, Stojkovic T, Psimaras D (2018) Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability. Acta Oncol 57(3):403\u2013411. \n                    https:\/\/doi.org\/10.1080\/0284186X.2017.1415462","journal-title":"Acta Oncol"},{"issue":"4","key":"3884_CR51","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/00043426-200304000-00010","volume":"25","author":"AR Chauvenet","year":"2003","unstructured":"Chauvenet AR, Shashi V, Selsky C, Morgan E, Kurtzberg J, Bell B (2003) Vincristine-induced neuropathy as the initial presentation of Charcot\u2013Marie\u2013Tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 25(4):316\u2013320. \n                    https:\/\/doi.org\/10.1097\/00043426-200304000-00010","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"3884_CR52","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1023\/A:1008389607293","volume":"11","author":"D Re","year":"2000","unstructured":"Re D, Schwenk A, Hegener P, Bamborschke S, Diehl V, Tesch H (2000) Guillain-Barre syndrome in a patient with non-Hodgkin\u2019s lymphoma. Ann Oncol 11(2):217\u2013220","journal-title":"Ann Oncol"},{"issue":"1","key":"3884_CR53","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4103\/1817-1745.154358","volume":"10","author":"B Bhushan","year":"2015","unstructured":"Bhushan B, Bhargava A, Kasundra GM, Shubhakaran K, Sood I (2015) Guillain-Barre syndrome in acute lymphoblastic leukemia: causal or coincidental. J Pediatr Neurosci 10(1):64\u201366. \n                    https:\/\/doi.org\/10.4103\/1817-1745.154358","journal-title":"J Pediatr Neurosci"},{"issue":"4","key":"3884_CR54","doi-asserted-by":"publisher","first-page":"252","DOI":"10.14740\/jocmr1856w","volume":"6","author":"N Okada","year":"2014","unstructured":"Okada N, Hanafusa T, Sakurada T, Teraoka K, Kujime T, Abe M, Shinohara Y, Kawazoe K, Minakuchi K (2014) Risk factors for early-onset peripheral neuropathy caused by vincristine in patients with a first administration of R-CHOP or R-CHOP-like chemotherapy. J Clin Med Res 6(4):252\u2013260. \n                    https:\/\/doi.org\/10.14740\/jocmr1856w","journal-title":"J Clin Med Res"},{"issue":"2","key":"3884_CR55","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1046\/j.1365-2141.2003.04430.x","volume":"122","author":"R Aplenc","year":"2003","unstructured":"Aplenc R, Glatfelter W, Han P, Rappaport E, La M, Cnaan A, Blackwood MA, Lange B, Rebbeck T (2003) CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br J Haematol 122(2):240\u2013244. \n                    https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04430.x","journal-title":"Br J Haematol"},{"issue":"10","key":"3884_CR56","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1182\/blood-2006-10-054528","volume":"109","author":"S Kishi","year":"2007","unstructured":"Kishi S, Cheng C, French D, Pei D, Das S, Cook EH, Hijiya N, Rizzari C, Rosner GL, Frudakis T, Pui CH, Evans WE, Relling MV (2007) Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 109(10):4151\u20134157. \n                    https:\/\/doi.org\/10.1182\/blood-2006-10-054528","journal-title":"Blood"},{"issue":"4","key":"3884_CR57","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/pbc.21435","volume":"50","author":"JL Renbarger","year":"2008","unstructured":"Renbarger JL, McCammack KC, Rouse CE, Hall SD (2008) Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer 50(4):769\u2013771. \n                    https:\/\/doi.org\/10.1002\/pbc.21435","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"3884_CR58","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/s1470-2045(10)70206-0","volume":"11","author":"A Broyl","year":"2010","unstructured":"Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P (2010) Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65\/GMMG-HD4 trial. Lancet Oncol 11(11):1057\u20131065. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(10)70206-0","journal-title":"Lancet Oncol"},{"issue":"3","key":"3884_CR59","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/pbc.22845","volume":"56","author":"A Egbelakin","year":"2011","unstructured":"Egbelakin A, Ferguson MJ, MacGill EA, Lehmann AS, Topletz AR, Quinney SK, Li L, McCammack KC, Hall SD, Renbarger JL (2011) Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 56(3):361\u2013367. \n                    https:\/\/doi.org\/10.1002\/pbc.22845","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"3884_CR60","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.2217\/pgs.14.68","volume":"15","author":"F Ceppi","year":"2014","unstructured":"Ceppi F, Langlois-Pelletier C, Gagne V, Rousseau J, Ciolino C, De Lorenzo S, Kevin KM, Cijov D, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Sinnett D, Laverdiere C, Krajinovic M (2014) Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics 15(8):1105\u20131116. \n                    https:\/\/doi.org\/10.2217\/pgs.14.68","journal-title":"Pharmacogenomics"},{"issue":"8","key":"3884_CR61","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jama.2015.0894","volume":"313","author":"B Diouf","year":"2015","unstructured":"Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, Zheng JJ, Yang W, Fan Y, Wheeler HE, Wing C, Delaney SM, Komatsu M, Paugh SW, McCorkle JR, Lu X, Winick NJ, Carroll WL, Loh ML, Hunger SP, Devidas M, Pui CH, Dolan ME, Relling MV, Evans WE (2015) Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313(8):815\u2013823. \n                    https:\/\/doi.org\/10.1001\/jama.2015.0894","journal-title":"JAMA"},{"issue":"3","key":"3884_CR62","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/cpt.506","volume":"101","author":"W Stock","year":"2017","unstructured":"Stock W, Diouf B, Crews KR, Pei D, Cheng C, Laumann K, Mandrekar SJ, Luger S, Advani A, Stone RM, Larson RA, Evans WE (2017) An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia. Clin Pharmacol Ther 101(3):391\u2013395. \n                    https:\/\/doi.org\/10.1002\/cpt.506","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3884_CR63","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/FPC.0000000000000191","volume":"26","author":"A Gutierrez-Camino","year":"2016","unstructured":"Gutierrez-Camino A, Martin-Guerrero I, Lopez-Lopez E, Echebarria-Barona A, Zabalza I, Ruiz I, Guerra-Merino I, Garcia-Orad A (2016) Lack of association of the CEP72 RS924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. Pharmacogenet Genom 26(2):100\u2013102. \n                    https:\/\/doi.org\/10.1097\/FPC.0000000000000191","journal-title":"Pharmacogenet Genom"},{"issue":"1","key":"3884_CR64","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/1078155214553143","volume":"22","author":"RP Sims","year":"2016","unstructured":"Sims RP (2016) The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia. J Oncol Pharm Pract 22(1):76\u201381. \n                    https:\/\/doi.org\/10.1177\/1078155214553143","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"3884_CR65","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2217\/pgs-2016-0001","volume":"17","author":"E Lopez-Lopez","year":"2016","unstructured":"Lopez-Lopez E, Gutierrez-Camino A, Astigarraga I, Navajas A, Echebarria-Barona A, Garcia-Miguel P, Garcia de Andoin N, Lobo C, Guerra-Merino I, Martin-Guerrero I, Garcia-Orad A (2016) Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. Pharmacogenomics 17(7):731\u2013741. \n                    https:\/\/doi.org\/10.2217\/pgs-2016-0001","journal-title":"Pharmacogenomics"},{"issue":"6","key":"3884_CR66","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/mph.0000000000000910","volume":"39","author":"H Kayilioglu","year":"2017","unstructured":"Kayilioglu H, Kocak U, Kan Karaer D, Percin EF, Sal E, Tekkesin F, Isik M, Oner N, Belen FB, Yilmaz Keskin E, Okur A, Albayrak M, Kaya Z, Pinarli FG, Yenicesu I, Karadeniz C, Oguz A, Gursel T (2017) Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population. J Pediatr Hematol Oncol 39(6):458\u2013462. \n                    https:\/\/doi.org\/10.1097\/mph.0000000000000910","journal-title":"J Pediatr Hematol Oncol"},{"key":"3884_CR67","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26854","author":"JL Skiles","year":"2018","unstructured":"Skiles JL, Chiang C, Li CH, Martin S, Smith EL, Olbara G, Jones DR, Vik TA, Mostert S, Abbink F, Kaspers GJ, Li L, Njuguna F, Sajdyk TJ, Renbarger JL (2018) CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. Pediatr Blood Cancer. \n                    https:\/\/doi.org\/10.1002\/pbc.26854","journal-title":"Pediatr Blood Cancer"},{"key":"3884_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1179","author":"GEB Wright","year":"2018","unstructured":"Wright GEB, Amstutz U, Drogemoller BI, Shih J, Rassekh SR, Hayden MR, Carleton BC, Ross CJD (2018) Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes. Clin Pharmacol Ther. \n                    https:\/\/doi.org\/10.1002\/cpt.1179","journal-title":"Clin Pharmacol Ther"},{"key":"3884_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26525","author":"AB Smitherman","year":"2017","unstructured":"Smitherman AB, Faircloth CB, Deal A, Troy M, Gold SH (2017) Vincristine toxicity with co-administration of fluconazole during induction therapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. \n                    https:\/\/doi.org\/10.1002\/pbc.26525","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"3884_CR70","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2169\/internalmedicine.47.0701","volume":"47","author":"N Takahashi","year":"2008","unstructured":"Takahashi N, Kameoka Y, Yamanaka Y, Ubukawa K, Saito K, Fujishima M, Fujishima N, Saito H, Hirokawa M, Scott SA, Sawada K (2008) Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma. Intern Med (Tokyo, Japan) 47(7):651\u2013653","journal-title":"Intern Med (Tokyo, Japan)"},{"issue":"5","key":"3884_CR71","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1097\/MPH.0000000000001220","volume":"40","author":"M Nikanjam","year":"2018","unstructured":"Nikanjam M, Sun A, Albers M, Mangalindin K, Song E, Vempaty H, Sam D, Capparelli EV (2018) Vincristine-associated neuropathy with antifungal usage: a kaiser northern California experience. J Pediatr Hematol Oncol 40(5):e273\u2013e277. \n                    https:\/\/doi.org\/10.1097\/MPH.0000000000001220","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"3884_CR72","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/BF01697985","volume":"71","author":"A Bohme","year":"1995","unstructured":"Bohme A, Ganser A, Hoelzer D (1995) Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 71(6):311\u2013312","journal-title":"Ann Hematol"},{"issue":"1","key":"3884_CR73","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3109\/08880018.2011.624163","volume":"29","author":"AC Teusink","year":"2012","unstructured":"Teusink AC, Ragucci D, Shatat IF, Kalpatthi R (2012) Potentiation of vincristine toxicity with concomitant fluconazole prophylaxis in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 29(1):62\u201367. \n                    https:\/\/doi.org\/10.3109\/08880018.2011.624163","journal-title":"Pediatr Hematol Oncol"},{"issue":"2","key":"3884_CR74","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1046\/j.1365-2257.1998.00103.x","volume":"20","author":"J Gillies","year":"1998","unstructured":"Gillies J, Hung KA, Fitzsimons E, Soutar R (1998) Severe vincristine toxicity in combination with itraconazole. Clin Lab Haematol 20(2):123\u2013124","journal-title":"Clin Lab Haematol"},{"issue":"10","key":"3884_CR75","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1111\/j.1651-2227.2001.tb03257.x","volume":"90","author":"M Kamaluddin","year":"2001","unstructured":"Kamaluddin M, McNally P, Breatnach F, O\u2019Marcaigh A, Webb D, O\u2019Dell E, Scanlon P, Butler K, O\u2019Meara A (2001) Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr 90(10):1204\u20131207","journal-title":"Acta Paediatr"},{"issue":"8","key":"3884_CR76","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/jac\/dkr223","volume":"66","author":"RM van Schie","year":"2011","unstructured":"van Schie RM, Bruggemann RJ, Hoogerbrugge PM, te Loo DM (2011) Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia. J Antimicrob Chemother 66(8):1853\u20131856. \n                    https:\/\/doi.org\/10.1093\/jac\/dkr223","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"3884_CR77","doi-asserted-by":"publisher","first-page":"E22","DOI":"10.3816\/CLML.2010.n.025","volume":"10","author":"MC Cheung","year":"2010","unstructured":"Cheung MC, Hicks LK, Leitch HA (2010) Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma. Clin Lymphoma Myeloma Leukemia 10(2):E22\u2013E25. \n                    https:\/\/doi.org\/10.3816\/CLML.2010.n.025","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"12","key":"3884_CR78","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.3109\/10428194.2012.697560","volume":"53","author":"HM Ezzat","year":"2012","unstructured":"Ezzat HM, Cheung MC, Hicks LK, Boro J, Montaner JS, Lima VD, Harris M, Leitch HA (2012) Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. Leukemia Lymphoma 53(12):2390\u20132396. \n                    https:\/\/doi.org\/10.3109\/10428194.2012.697560","journal-title":"Leukemia Lymphoma"},{"issue":"3","key":"3884_CR79","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1200\/jco.1996.14.3.935","volume":"14","author":"M Weintraub","year":"1996","unstructured":"Weintraub M, Adde MA, Venzon DJ, Shad AT, Horak ID, Neely JE, Seibel NL, Gootenberg J, Arndt C, Nieder ML, Magrath IT (1996) Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J Clin Oncol 14(3):935\u2013940. \n                    https:\/\/doi.org\/10.1200\/jco.1996.14.3.935","journal-title":"J Clin Oncol"},{"issue":"3","key":"3884_CR80","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/1097-0142(19830201)51:3<423::AID-CNCR2820510311>3.0.CO;2-3","volume":"51","author":"JR Ryan","year":"1983","unstructured":"Ryan JR, Emami A (1983) Vincristine neurotoxicity with residual equinocavus deformity in children with acute leukemia. Cancer 51(3):423\u2013425","journal-title":"Cancer"},{"issue":"10","key":"3884_CR81","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1001\/archneur.1992.00530340043016","volume":"49","author":"B van Kooten","year":"1992","unstructured":"van Kooten B, van Diemen HA, Groenhout KM, Huijgens PC, Ossenkoppele GJ, Nauta JJ, Heimans JJ (1992) A pilot study on the influence of a corticotropin (4\u20139) analogue on Vinca alkaloid-induced neuropathy. Arch Neurol 49(10):1027\u20131031","journal-title":"Arch Neurol"},{"issue":"6","key":"3884_CR82","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s12098-010-0096-z","volume":"77","author":"S Akbayram","year":"2010","unstructured":"Akbayram S, Akgun C, Dogan M, Sayin R, Caksen H, Oner AF (2010) Use of pyridoxine and pyridostigmine in children with vincristine-induced neuropathy. Indian J Pediatr 77(6):681\u2013683. \n                    https:\/\/doi.org\/10.1007\/s12098-010-0096-z","journal-title":"Indian J Pediatr"},{"issue":"6","key":"3884_CR83","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/pbc.25384","volume":"62","author":"SM Bradfield","year":"2015","unstructured":"Bradfield SM, Sandler E, Geller T, Tamura RN, Krischer JP (2015) Glutamic acid not beneficial for the prevention of vincristine neurotoxicity in children with cancer. Pediatr Blood Cancer 62(6):1004\u20131010. \n                    https:\/\/doi.org\/10.1002\/pbc.25384","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"3884_CR84","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00520-016-3441-6","volume":"25","author":"S Sands","year":"2017","unstructured":"Sands S, Ladas EJ, Kelly KM, Weiner M, Lin M, Ndao DH, Dave A, Vahdat LT, Bender JG (2017) Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer. Support Care Cancer 25(3):701\u2013708. \n                    https:\/\/doi.org\/10.1007\/s00520-016-3441-6","journal-title":"Support Care Cancer"},{"issue":"3","key":"3884_CR85","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00432-003-0524-9","volume":"130","author":"S Koeppen","year":"2004","unstructured":"Koeppen S, Verstappen CC, Korte R, Scheulen ME, Strumberg D, Postma TJ, Heimans JJ, Huijgens PC, Kiburg B, Renzing-Kohler K, Diener HC (2004) Lack of neuroprotection by an ACTH (4\u20139) analogue. A randomized trial in patients treated with vincristine for Hodgkin\u2019s or non-Hodgkin\u2019s lymphoma. J Cancer Res Clin Oncol 130(3):153\u2013160. \n                    https:\/\/doi.org\/10.1007\/s00432-003-0524-9","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"3884_CR86","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1177\/0883073813491829","volume":"29","author":"P Jain","year":"2014","unstructured":"Jain P, Gulati S, Seth R, Bakhshi S, Toteja GS, Pandey RM (2014) Vincristine-induced neuropathy in childhood all (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics. J Child Neurol 29(7):932\u2013937. \n                    https:\/\/doi.org\/10.1177\/0883073813491829","journal-title":"J Child Neurol"},{"issue":"1","key":"3884_CR87","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/(SICI)1097-0142(19980101)82:1<200::AID-CNCR87>3.0.CO;2-5","volume":"82","author":"AH Harila-Saari","year":"1998","unstructured":"Harila-Saari AH, Vainionp\u00e4\u00e4 LK, Kovala TT, Tolonen EU, Lanning BM (1998) Nerve lesions after therapy for childhood acute lymphoblastic leukemia. Cancer 82(1):200\u2013207. \n                    https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19980101)82:1%3c200:AID-CNCR87%3e3.0.CO;2-5","journal-title":"Cancer"},{"issue":"6113","key":"3884_CR88","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/bmj.1.6113.610","volume":"1","author":"SM Watkins","year":"1978","unstructured":"Watkins SM, Griffin JP (1978) High incidence of vincristine-induced neuropathy in lymphomas. BMJ 1(6113):610\u2013612","journal-title":"BMJ"},{"key":"3884_CR89","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26471","author":"CG Tay","year":"2017","unstructured":"Tay CG, Lee VWM, Ong LC, Goh KJ, Ariffin H, Fong CY (2017) Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia. Pediatric Blood Cancer. \n                    https:\/\/doi.org\/10.1002\/pbc.26471","journal-title":"Pediatric Blood Cancer"},{"issue":"1","key":"3884_CR90","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF01050259","volume":"15","author":"TJ Postma","year":"1993","unstructured":"Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ (1993) Long-term effects of vincristine on the peripheral nervous system. J Neurooncol 15(1):23\u201327","journal-title":"J Neurooncol"},{"issue":"6","key":"3884_CR91","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1212\/01.wnl.0000154642.45474.28","volume":"64","author":"CC Verstappen","year":"2005","unstructured":"Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B, Postma TJ (2005) Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 64(6):1076\u20131077. \n                    https:\/\/doi.org\/10.1212\/01.wnl.0000154642.45474.28","journal-title":"Neurology"},{"issue":"10","key":"3884_CR92","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1002\/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G","volume":"73","author":"N Haim","year":"1994","unstructured":"Haim N, Epelbaum R, Ben-Shahar M, Yarnitsky D, Simri W, Robinson E (1994) Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 73(10):2515\u20132519","journal-title":"Cancer"},{"issue":"1","key":"3884_CR93","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/jns.12114","volume":"20","author":"EM Lavoie Smith","year":"2015","unstructured":"Lavoie Smith EM, Li L, Chiang C, Thomas K, Hutchinson RJ, Wells EM, Ho RH, Skiles J, Chakraborty A, Bridges CM, Renbarger J (2015) Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. J Periph Nerv Syst 20(1):37\u201346. \n                    https:\/\/doi.org\/10.1111\/jns.12114","journal-title":"J Periph Nerv Syst"},{"issue":"8","key":"3884_CR94","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s11136-010-9670-0","volume":"19","author":"BJ Kim","year":"2010","unstructured":"Kim BJ, Park HR, Roh HJ, Jeong DS, Kim BS, Park KW, Cho SC, So YT, Oh SY, Kim SJ (2010) Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Q Life Res 19(8):1097\u20131103. \n                    https:\/\/doi.org\/10.1007\/s11136-010-9670-0","journal-title":"Q Life Res"},{"issue":"2","key":"3884_CR95","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/BF02072486","volume":"152","author":"L Vainionpaa","year":"1993","unstructured":"Vainionpaa L (1993) Clinical neurological findings of children with acute lymphoblastic leukaemia at diagnosis and during treatment. Eur J Pediatr 152(2):115\u2013119. \n                    https:\/\/doi.org\/10.1007\/BF02072486","journal-title":"Eur J Pediatr"},{"issue":"1","key":"3884_CR96","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/pbc.26204","volume":"64","author":"LS Gilchrist","year":"2017","unstructured":"Gilchrist LS, Tanner LR, Ness KK (2017) Short-term recovery of chemotherapy-induced peripheral neuropathy after treatment for pediatric non-CNS cancer. Pediatr Blood Cancer 64(1):180\u2013187. \n                    https:\/\/doi.org\/10.1002\/pbc.26204","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"3884_CR97","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207\u2013214","journal-title":"Cancer"},{"issue":"32","key":"3884_CR98","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1200\/jco.2007.12.4784","volume":"25","author":"A Trotti","year":"2007","unstructured":"Trotti A, Colevas AD, Setser A, Basch E (2007) Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 25(32):5121\u20135127. \n                    https:\/\/doi.org\/10.1200\/jco.2007.12.4784","journal-title":"J Clin Oncol"},{"issue":"3","key":"3884_CR99","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","volume":"12","author":"G Cavaletti","year":"2007","unstructured":"Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C, Zara G, Plasmati R, Pastorelli F, Caraceni A, Pace A, Manicone M, Lissoni A, Colombo N, Bianchi G, Zanna C (2007) The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Periph Nerv Syst JPNS 12(3):210\u2013215. \n                    https:\/\/doi.org\/10.1111\/j.1529-8027.2007.00141.x","journal-title":"J Periph Nerv Syst JPNS"},{"issue":"1","key":"3884_CR100","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.spen.2012.02.011","volume":"19","author":"L Gilchrist","year":"2012","unstructured":"Gilchrist L (2012) Chemotherapy-induced peripheral neuropathy in pediatric cancer patients. Semin Pediatr Neurol 19(1):9\u201317. \n                    https:\/\/doi.org\/10.1016\/j.spen.2012.02.011","journal-title":"Semin Pediatr Neurol"},{"issue":"11","key":"3884_CR101","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1080\/14737140.2017.1374856","volume":"17","author":"M Bakogeorgos","year":"2017","unstructured":"Bakogeorgos M, Georgoulias V (2017) Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy. Expert Rev Anticancer Ther 17(11):1045\u20131060. \n                    https:\/\/doi.org\/10.1080\/14737140.2017.1374856","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"3884_CR102","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/1040-8428(93)90006-P","volume":"14","author":"M Hussain","year":"1993","unstructured":"Hussain M, Wozniak AJ, Edelstein MB (1993) Neurotoxicity of antineoplastic agents. Crit Rev Oncol Hematol 14(1):61\u201375","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"3884_CR103","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.ejca.2008.04.018","volume":"44","author":"S Wolf","year":"2008","unstructured":"Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44(11):1507\u20131515. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2008.04.018","journal-title":"Eur J Cancer"},{"issue":"1","key":"3884_CR104","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/PL00007853","volume":"249","author":"S Quasthoff","year":"2002","unstructured":"Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249(1):9\u201317","journal-title":"J Neurol"},{"issue":"Suppl. 4","key":"3884_CR105","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/neuonc\/nos203","volume":"14","author":"W Grisold","year":"2012","unstructured":"Grisold W, Cavaletti G, Windebank AJ (2012) Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-oncology 14(Suppl. 4):45\u201354. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nos203","journal-title":"Neuro-oncology"},{"issue":"12","key":"3884_CR106","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.2337\/dc06-1499","volume":"29","author":"MC Gulliford","year":"2006","unstructured":"Gulliford MC, Charlton J, Latinovic R (2006) Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 29(12):2728\u20132729. \n                    https:\/\/doi.org\/10.2337\/dc06-1499","journal-title":"Diabetes Care"},{"issue":"8","key":"3884_CR107","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1124\/dmd.106.009902","volume":"34","author":"JB Dennison","year":"2006","unstructured":"Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD (2006) Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 34(8):1317\u20131327. \n                    https:\/\/doi.org\/10.1124\/dmd.106.009902","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"3884_CR108","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/86882","volume":"27","author":"P Kuehl","year":"2001","unstructured":"Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27(4):383\u2013391. \n                    https:\/\/doi.org\/10.1038\/86882","journal-title":"Nat Genet"},{"issue":"2","key":"3884_CR109","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","volume":"38","author":"K Venkatakrishnan","year":"2000","unstructured":"Venkatakrishnan K, von Moltke LL, Greenblatt DJ (2000) Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 38(2):111\u2013180. \n                    https:\/\/doi.org\/10.2165\/00003088-200038020-00002","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"3884_CR110","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1128\/AAC.46.1.160-165.2002","volume":"46","author":"E-j Wang","year":"2002","unstructured":"Wang E-j, Lew K, Casciano CN, Clement RP, Johnson WW (2002) Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 46(1):160\u2013165. \n                    https:\/\/doi.org\/10.1128\/AAC.46.1.160-165.2002","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03884-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03884-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03884-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T19:10:50Z","timestamp":1592334650000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03884-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,18]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["3884"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03884-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,18]]},"assertion":[{"value":"29 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Author M.L.M declares that she has no conflict of interest. Author H.D declares that she has no conflict of interest. Author N.E declares that he has no conflict of interest. Author P.J declares that he has no conflict of interest. Author J.M declares that he has no conflict of interest. Author K.D declares that she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}